116 related articles for article (PubMed ID: 17252153)
1. Risk of malignancy in myasthenia gravis patients exposed to azathioprine therapy for a median period of 3 years.
Rawoot A; Little F; Heckmann JM
S Afr Med J; 2006 Dec; 96(12):1249-51. PubMed ID: 17252153
[No Abstract] [Full Text] [Related]
2. Low-dose azathioprine effectively suppresses clinical and immunological manifestations of generalized myasthenia.
Finsterer J; Frank M; Krexner E
South Med J; 2010 Feb; 103(2):182-4. PubMed ID: 20065912
[No Abstract] [Full Text] [Related]
3. Cancer occurrence following azathioprine treatment in myasthenia gravis patients: A systematic review and meta-analysis.
Zhang Z; Wang M; Xu L; Jiang B; Jin T; Shi T; Xu B
J Clin Neurosci; 2021 Jun; 88():70-74. PubMed ID: 33992207
[TBL] [Abstract][Full Text] [Related]
4. Sweet syndrome as a manifestation of azathioprine hypersensitivity.
El-Azhary RA; Brunner KL; Gibson LE
Mayo Clin Proc; 2008 Sep; 83(9):1026-30. PubMed ID: 18775203
[TBL] [Abstract][Full Text] [Related]
5. [Myasthenia gravis. Opportunistic cytomegalovirus infection after long-term azathioprine therapy].
Eisensehr I; Büttner U; Witt TN; von Appen K; Spuler S
Nervenarzt; 1999 Oct; 70(10):924-6. PubMed ID: 10554786
[TBL] [Abstract][Full Text] [Related]
6. Association of primary central nervous system lymphoma with long-term azathioprine therapy for myasthenia gravis?
Herrlinger U; Weller M; Dichgans J; Melms A
Ann Neurol; 2000 May; 47(5):682-3. PubMed ID: 10805346
[No Abstract] [Full Text] [Related]
7. Nonmelanoma skin cancer risk awareness in azathioprine-treated myasthenia gravis patients.
McGurgan IJ; McGuigan C
Brain Behav; 2015 Oct; 5(10):e00396. PubMed ID: 26516615
[TBL] [Abstract][Full Text] [Related]
8. [Hypersensitivity to azathioprine can simulate an aggravation of myasthenia].
Chevrel G; Moreau T; Vial T; Payen C; Confavreux C
Therapie; 1998; 53(1):77-8. PubMed ID: 9773103
[No Abstract] [Full Text] [Related]
9. [A post-thymomectomy case of myasthenia gravis which developed nephrotic syndrome with membranous nephropathy during azathioprine administration].
Konishi T; Miki S; Yoshida A; Tei M
Rinsho Shinkeigaku; 1996 Jul; 36(7):864-8. PubMed ID: 8952354
[TBL] [Abstract][Full Text] [Related]
10. Azathioprine in the treatment of myasthenia gravis.
Witte AS; Cornblath DR; Parry GJ; Lisak RP; Schatz NJ
Ann Neurol; 1984 Jun; 15(6):602-5. PubMed ID: 6742794
[TBL] [Abstract][Full Text] [Related]
11. Neutrophilic dermatosis caused by azathioprine hypersensitivity.
Hurtado-Garcia R; Escribano-Stablé JC; Pascual Jc; Devesa P; Matarredona J; Hurtado-Garcia R
Int J Dermatol; 2012 Dec; 51(12):1522-5. PubMed ID: 22471306
[No Abstract] [Full Text] [Related]
12. Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine.
Pedersen EG; Pottegård A; Hallas J; Friis S; Hansen K; Jensen PE; Gaist D
Eur J Neurol; 2014 Mar; 21(3):454-8. PubMed ID: 24330255
[TBL] [Abstract][Full Text] [Related]
13. Long-term, low-dose immunosuppression for myasthenia does not affect collateral, asymptomatic sclerosing cholangitis.
Finsterer J; Höflich S
Arq Neuropsiquiatr; 2012 Feb; 70(2):158-9. PubMed ID: 22311226
[No Abstract] [Full Text] [Related]
14. Visceral leishmaniasis masquerading as drug-induced pancytopenia in myasthenia gravis.
Nath UK; Bhattacharyya D; Chattopadhya D; Dhingra G; Azad S; Mohanty A
Drug Discov Ther; 2021 Mar; 15(1):48-50. PubMed ID: 33612571
[TBL] [Abstract][Full Text] [Related]
15. [Myasthenic crisis caused by azathioprine-induced fever].
Tumani H; George A; Nau R
Nervenarzt; 1997 Apr; 68(4):336-8. PubMed ID: 9273463
[TBL] [Abstract][Full Text] [Related]
16. Azathioprine as a single immunosuppressive drug in the treatment of myasthenia gravis.
Cosi V; Lombardi M; Erbetta A; Piccolo G
Acta Neurol (Napoli); 1993 Apr; 15(2):123-31. PubMed ID: 8328322
[TBL] [Abstract][Full Text] [Related]
17. Use of azathioprine for non-thymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark.
Pedersen EG; Pottegård A; Hallas J; Friis S; Hansen K; Jensen PE; Gaist D
Eur J Neurol; 2013 Jun; 20(6):942-8. PubMed ID: 23448676
[TBL] [Abstract][Full Text] [Related]
18. Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis.
Hohlfeld R; Michels M; Heininger K; Besinger U; Toyka KV
Neurology; 1988 Feb; 38(2):258-61. PubMed ID: 3340289
[TBL] [Abstract][Full Text] [Related]
19. Safety of long-term combined immunosuppressive treatment in myasthenia gravis--analysis of adverse effects of 163 patients.
Rozsa C; Lovas G; Fornadi L; Szabo G; Komoly S
Eur J Neurol; 2006 Sep; 13(9):947-52. PubMed ID: 16930359
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus-associated hemophagocytic lymphohistiocytosis in a patient with myasthenia gravis treated with azathioprine.
Frederiksen JK; Ross CW
Blood; 2014 Apr; 123(15):2290. PubMed ID: 24895699
[No Abstract] [Full Text] [Related]
[Next] [New Search]
